This page has only limited features, please log in for full access.

Dr. Sarah Almahboub
King Fahd Medical Research Center, King Abdulaziz University, Saudi Arabia

Basic Info

Basic Info is private.

Research Keywords & Expertise

0 Molecular
0 Vacancies
0 CoronaVirus
0 Microbiologie
0 pseudovirus

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Journal article
Published: 20 July 2021 in Viruses
Reads 0
Downloads 0

Healthcare workers (HCWs) are at high risk for SARS-CoV-2 infection compared to the general population. Here, we aimed to evaluate and characterize the SARS-CoV-2 seropositivity rate in randomly collected samples among HCWs from the largest referral hospitals and quarantine sites during the peak of the COVID-19 epidemic in the city of Jeddah, the second largest city in Saudi Arabia, using a cross-sectional analytic study design. Out of 693 participants recruited from 29 June to 10 August 2020, 223 (32.2%, 95% CI: 28.8–35.8) were found to be confirmed seropositive for SARS-CoV-2 antibodies, and among those 197 (88.3%) had never been diagnosed with COVID-19. Seropositivity was not significantly associated with participants reporting COVID-19 compatible symptoms as most seropositive HCW participants 140 (62.8%) were asymptomatic. The large proportion of asymptomatic SARS-CoV-2 cases detected in our study demands periodic testing as a general hospital policy.

ACS Style

Rowa Alhabbab; Ahdab Alsaieedi; Abdullah Algaissi; Sara Almahboub; Rajaa Al-Raddadi; Omaima Shabouni; Rahaf Alhabbab; Abdulelah Alfaraj; Sawsan Alamri; Najwa Aljehani; Rwaa Abdulal; Mohamed Alfaleh; Turki Abujamel; Almohanad Alkayyal; Ahmad Mahmoud; Adel Abuzenadah; Anwar Hashem. Seroprevalence of SARS-CoV-2 Binding and Neutralizing Antibodies in Healthcare Workers during the Epidemic Peak in Referral Hospitals and Quarantine Sites: Saudi Arabia. Viruses 2021, 13, 1413 .

AMA Style

Rowa Alhabbab, Ahdab Alsaieedi, Abdullah Algaissi, Sara Almahboub, Rajaa Al-Raddadi, Omaima Shabouni, Rahaf Alhabbab, Abdulelah Alfaraj, Sawsan Alamri, Najwa Aljehani, Rwaa Abdulal, Mohamed Alfaleh, Turki Abujamel, Almohanad Alkayyal, Ahmad Mahmoud, Adel Abuzenadah, Anwar Hashem. Seroprevalence of SARS-CoV-2 Binding and Neutralizing Antibodies in Healthcare Workers during the Epidemic Peak in Referral Hospitals and Quarantine Sites: Saudi Arabia. Viruses. 2021; 13 (7):1413.

Chicago/Turabian Style

Rowa Alhabbab; Ahdab Alsaieedi; Abdullah Algaissi; Sara Almahboub; Rajaa Al-Raddadi; Omaima Shabouni; Rahaf Alhabbab; Abdulelah Alfaraj; Sawsan Alamri; Najwa Aljehani; Rwaa Abdulal; Mohamed Alfaleh; Turki Abujamel; Almohanad Alkayyal; Ahmad Mahmoud; Adel Abuzenadah; Anwar Hashem. 2021. "Seroprevalence of SARS-CoV-2 Binding and Neutralizing Antibodies in Healthcare Workers during the Epidemic Peak in Referral Hospitals and Quarantine Sites: Saudi Arabia." Viruses 13, no. 7: 1413.

Journal article
Published: 04 December 2020 in Viruses
Reads 0
Downloads 0

The Coronavirus Disease 2019 (COVID-19), caused by SARS-CoV-2, continues to spread globally with significantly high morbidity and mortality rates. Antigen-specific responses are of unquestionable value for clinical management of COVID-19 patients. Here, we investigated the kinetics of IgM, IgG against the spike (S) and nucleoproteins (N) proteins and their neutralizing capabilities in hospitalized COVID-19 patients with different disease presentations (i.e., mild, moderate or severe), need for intensive care units (ICU) admission or outcomes (i.e., survival vs death). We show that SARS-CoV-2 specific IgG, IgM and neutralizing antibodies (nAbs) were readily detectable in almost all COVID-19 patients with various clinical presentations. Interestingly, significantly higher levels of nAbs as well as anti-S1 and -N IgG and IgM antibodies were found in patients with more severe symptoms, patients requiring admission to ICU or those with fatal outcomes. More importantly, early after symptoms onset, we found that the levels of anti-N antibodies correlated strongly with disease severity. Collectively, these findings provide new insights into the kinetics of antibody responses in COVID-19 patients with different disease severity.

ACS Style

Anwar M. Hashem; Abdullah Algaissi; Sarah A. Almahboub; Mohamed A. Alfaleh; Turki S. Abujamel; Sawsan S. Alamri; Khalid A. Alluhaybi; Haya I. Hobani; Rahaf H. AlHarbi; Reem M. Alsulaiman; M-Zaki ElAssouli; Sharif Hala; Naif K. Alharbi; Rowa Y. Alhabbab; Ahdab A. AlSaieedi; Wesam H. Abdulaal; Abdullah Bukhari; Afrah A. Al-Somali; Fadwa S. Alofi; Asim A. Khogeer; Arnab Pain; Almohanad A. Alkayyal; Naif A. M. Almontashiri; Ahmad Bakur Mahmoud; Xuguang Li. Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients. Viruses 2020, 12, 1390 .

AMA Style

Anwar M. Hashem, Abdullah Algaissi, Sarah A. Almahboub, Mohamed A. Alfaleh, Turki S. Abujamel, Sawsan S. Alamri, Khalid A. Alluhaybi, Haya I. Hobani, Rahaf H. AlHarbi, Reem M. Alsulaiman, M-Zaki ElAssouli, Sharif Hala, Naif K. Alharbi, Rowa Y. Alhabbab, Ahdab A. AlSaieedi, Wesam H. Abdulaal, Abdullah Bukhari, Afrah A. Al-Somali, Fadwa S. Alofi, Asim A. Khogeer, Arnab Pain, Almohanad A. Alkayyal, Naif A. M. Almontashiri, Ahmad Bakur Mahmoud, Xuguang Li. Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients. Viruses. 2020; 12 (12):1390.

Chicago/Turabian Style

Anwar M. Hashem; Abdullah Algaissi; Sarah A. Almahboub; Mohamed A. Alfaleh; Turki S. Abujamel; Sawsan S. Alamri; Khalid A. Alluhaybi; Haya I. Hobani; Rahaf H. AlHarbi; Reem M. Alsulaiman; M-Zaki ElAssouli; Sharif Hala; Naif K. Alharbi; Rowa Y. Alhabbab; Ahdab A. AlSaieedi; Wesam H. Abdulaal; Abdullah Bukhari; Afrah A. Al-Somali; Fadwa S. Alofi; Asim A. Khogeer; Arnab Pain; Almohanad A. Alkayyal; Naif A. M. Almontashiri; Ahmad Bakur Mahmoud; Xuguang Li. 2020. "Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients." Viruses 12, no. 12: 1390.

Other
Published: 23 September 2020
Reads 0
Downloads 0

The Coronavirus Disease 2019 (COVID-19), caused by the novel SARS-CoV-2, continues to spread globally with significantly high morbidity and mortality rates. Immunological surrogate markers, in particular antigen-specific responses, are of unquestionable value for clinical management of patients with COVID-19. Here, we investigated the kinetics of IgM, IgG against the spike (S) and nucleoproteins (N) proteins and their neutralizing capabilities in hospitalized patients with RT-PCR confirmed COVID-19 infection. Our data show that SARS-CoV-2 specific IgG, IgM and neutralizing antibodies (nAbs) were readily detectable in almost all COVID-19 patients with various clinical presentations. Notably, anti-S and -N IgG, peaked 20-40 day after disease onset, and were still detectable for at least up to 70 days, with nAbs observed during the same time period. Moreover, nAbs titers were strongly correlated with IgG antibodies. Significantly higher levels of nAbs as well as anti-S1 and N IgG and IgM antibodies were found in patients with more severe clinical presentations, patients requiring admission to intensive care units (ICU) or those with fatal outcomes. Interestingly, lower levels of antibodies, particularly anti-N IgG and IgM in the first 15 days after symptoms onset, were found in survivors and those with mild clinical presentations. Collectively, these findings provide new insights into the characteristics and kinetics of antibody responses in COVID-19 patients with different disease severity.

ACS Style

Anwar M Hashem; Abdullah Algaissi; Sarah A Almahboub; Mohamed A Alfaleh; Turki S Abujamel; Sawsan S Alamri; Khalid A Alluhaybi; Haya I Hobani; Rahaf H AlHarbi; Reem M Alsulaiman; M-Zaki ElAssouli; Sharif Hala; Naif K Alharbi; Rowa Y Alhabbab; Ahdab A AlSaieedi; Wesam H Abdulaal; Abdullah Bukhari; Afrah A Al-Somali; Fadwa S Alofi; Asim A Khogeer; Arnab Pain; Almohanad A Alkayyal; Naif Am Almontashiri; Ahmad Bakur Mahmoud; Xuguang Li. Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients. 2020, 1 .

AMA Style

Anwar M Hashem, Abdullah Algaissi, Sarah A Almahboub, Mohamed A Alfaleh, Turki S Abujamel, Sawsan S Alamri, Khalid A Alluhaybi, Haya I Hobani, Rahaf H AlHarbi, Reem M Alsulaiman, M-Zaki ElAssouli, Sharif Hala, Naif K Alharbi, Rowa Y Alhabbab, Ahdab A AlSaieedi, Wesam H Abdulaal, Abdullah Bukhari, Afrah A Al-Somali, Fadwa S Alofi, Asim A Khogeer, Arnab Pain, Almohanad A Alkayyal, Naif Am Almontashiri, Ahmad Bakur Mahmoud, Xuguang Li. Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients. . 2020; ():1.

Chicago/Turabian Style

Anwar M Hashem; Abdullah Algaissi; Sarah A Almahboub; Mohamed A Alfaleh; Turki S Abujamel; Sawsan S Alamri; Khalid A Alluhaybi; Haya I Hobani; Rahaf H AlHarbi; Reem M Alsulaiman; M-Zaki ElAssouli; Sharif Hala; Naif K Alharbi; Rowa Y Alhabbab; Ahdab A AlSaieedi; Wesam H Abdulaal; Abdullah Bukhari; Afrah A Al-Somali; Fadwa S Alofi; Asim A Khogeer; Arnab Pain; Almohanad A Alkayyal; Naif Am Almontashiri; Ahmad Bakur Mahmoud; Xuguang Li. 2020. "Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients." , no. : 1.

Preprint
Published: 02 July 2020
Reads 0
Downloads 0

As the coronavirus disease 2019 (COVID-19), which is caused by the novel SARS-CoV-2, continues to spread rapidly around the world, there is a need for well validated serological assays that allow the detection of viral specific antibody responses in COVID-19 patients or recovered individuals. In this study, we established and used multiple indirect Enzyme Linked Immunosorbent Assay (ELISA)-based serological assays to study the antibody response in COVID-19 patients. In order to validate the assays we determined the cut off values, sensitivity and specificity of the assays using sera collected from pre-pandemic healthy controls, COVID-19 patients at different time points after disease-onset, and seropositive sera to other human coronaviruses. The developed SARS-CoV-2 S1 subunit of the spike glycoprotein and nucleocapsid (N)-based ELISAs not only showed high specificity and sensitivity but also did not show any cross-reactivity with other CoVs. We also show that all RT-PCR confirmed COVID-19 patients tested in our study developed both virus specific IgM and IgG antibodies as early as week one after disease onset. Our data also suggest that the inclusion of both S1 and N in serological testing would capture as many potential SARS-CoV-2 positive cases as possible than using any of them alone. This is specifically important for tracing contacts and cases and conducting large-scale epidemiological studies to understand the true extent of virus spread in populations.

ACS Style

Abdullah Algaissi; Mohamed A. AlFaleh; Sherif Hala; Turki S. Abujamel; Sawsan S. Alamri; Sarah A Almahboub; Khalid A. Alluhaybi; Haya I. Hobani; Reem M. Alsulaiman; Rahaf H. Alharbi; M-Zaki El-Assouli; Rowa Y Alhabbab; Ahdab A. AlSaieedi; Wesam H. Abdulaal; Afrah A. Al-Somali; Fadwa S. Alofi; Asim A. Khogeer; Ahmad Bakur Mahmoud; Almohanad A Alkayyal; Naif A.M. Almontashiri; Arnab Pain; Anwar M. Hashem. SARS-CoV-2 S1 and N-Based Serological Assays Reveal Rapid Seroconversion and Induction of Specific Antibody Response in COVID-19 Patients. 2020, 1 .

AMA Style

Abdullah Algaissi, Mohamed A. AlFaleh, Sherif Hala, Turki S. Abujamel, Sawsan S. Alamri, Sarah A Almahboub, Khalid A. Alluhaybi, Haya I. Hobani, Reem M. Alsulaiman, Rahaf H. Alharbi, M-Zaki El-Assouli, Rowa Y Alhabbab, Ahdab A. AlSaieedi, Wesam H. Abdulaal, Afrah A. Al-Somali, Fadwa S. Alofi, Asim A. Khogeer, Ahmad Bakur Mahmoud, Almohanad A Alkayyal, Naif A.M. Almontashiri, Arnab Pain, Anwar M. Hashem. SARS-CoV-2 S1 and N-Based Serological Assays Reveal Rapid Seroconversion and Induction of Specific Antibody Response in COVID-19 Patients. . 2020; ():1.

Chicago/Turabian Style

Abdullah Algaissi; Mohamed A. AlFaleh; Sherif Hala; Turki S. Abujamel; Sawsan S. Alamri; Sarah A Almahboub; Khalid A. Alluhaybi; Haya I. Hobani; Reem M. Alsulaiman; Rahaf H. Alharbi; M-Zaki El-Assouli; Rowa Y Alhabbab; Ahdab A. AlSaieedi; Wesam H. Abdulaal; Afrah A. Al-Somali; Fadwa S. Alofi; Asim A. Khogeer; Ahmad Bakur Mahmoud; Almohanad A Alkayyal; Naif A.M. Almontashiri; Arnab Pain; Anwar M. Hashem. 2020. "SARS-CoV-2 S1 and N-Based Serological Assays Reveal Rapid Seroconversion and Induction of Specific Antibody Response in COVID-19 Patients." , no. : 1.

Preprint
Published: 23 May 2020
Reads 0
Downloads 0

Emerging highly pathogenic human coronaviruses (CoVs) represent a serious ongoing threat to the public health worldwide. The spike (S) proteins of CoVs are surface glycoproteins that facilitate viral entry into host cells via attachment to their respective cellular receptors. The S protein is believed to be a major immunogenic component of CoVs and a target for neutralizing antibodies (nAbs) and most candidate vaccines. Development of a safe and convenient assay is thus urgently needed to determine the prevalence of CoVs nAbs in the population, to study immune response in infected individuals, and to aid in vaccines and viral entry inhibitors evaluation. While live virus-based neutralization assays are used as gold standard serological methods to detect and measure nAbs, handling of highly pathogenic live CoVs requires strict bio-containment conditions in biosafety level-3 laboratories. On the other hand, use of replication-incompetent pseudoviruses bearing CoVs S proteins could represent a safe and useful method to detect nAbs in serum samples under biosafety level-2 conditions. Here, we describe a detailed protocol of a safe and convenient assay to generate vesicular stomatitis virus (VSV)-based pseudoviruses to evaluate and measure nAbs against highly pathogenic CoVs. The protocol covers methods to produce VSV pseudovirus bearing the S protein of the Middle East respiratory syndrome-CoV (MERS-CoV) and the severe acute respiratory syndrome-CoV-2 (SARS-CoV-2), pseudovirus titration, and pseudovirus neutralizing assay. Such assay could be adapted by different laboratories and researchers working on highly pathogenic CoVs without the need to handle live viruses in biosafety level-3 environment.

ACS Style

Sarah A. Almahboub; Abdullah Algaissi; Mohamed A. AlFaleh; M-Zaki ElAssouli; Anwar M. Hashem. Evaluation of Neutralizing Antibodies against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus (Vsv) Pseudovirus-Based Assay. 2020, 1 .

AMA Style

Sarah A. Almahboub, Abdullah Algaissi, Mohamed A. AlFaleh, M-Zaki ElAssouli, Anwar M. Hashem. Evaluation of Neutralizing Antibodies against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus (Vsv) Pseudovirus-Based Assay. . 2020; ():1.

Chicago/Turabian Style

Sarah A. Almahboub; Abdullah Algaissi; Mohamed A. AlFaleh; M-Zaki ElAssouli; Anwar M. Hashem. 2020. "Evaluation of Neutralizing Antibodies against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus (Vsv) Pseudovirus-Based Assay." , no. : 1.